Status: Recruiting
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC). Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied
Participants needed: 23
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Okayama UniversityUpdated: Mar 20, 2025Locations: 3
Eligibility criteria
Male/female subjects who are at least 18 years of age on the day of signing info... [+10]
Subjects who has a positive urine pregnancy test within 72 hours prior to regist... [+27]